NBIX Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of 16.43% compared to Neurocrine Biosciences's net margin of --. Neurocrine Biosciences's return on equity of 13.72% beat Perspective Therapeutics's return on equity of --.

Neurocrine Biosciences has a consensus price target of $161.42, signalling upside risk potential of 70.12%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 602.09%. Given that Perspective Therapeutics has higher upside potential than Neurocrine Biosciences, analysts believe Perspective Therapeutics is more attractive than Neurocrine Biosciences.

Neurocrine Biosciences has a beta of 0.334, which suggesting that the stock is 66.575% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Neurocrine Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Neurocrine Biosciences quarterly revenues are $627.7M, which are larger than Perspective Therapeutics quarterly revenues of --. Neurocrine Biosciences's net income of $103.1M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Neurocrine Biosciences's price-to-earnings ratio is 28.84x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences is 4.18x versus 13.27x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of 16.43% compared to Neurocrine Biosciences's net margin of 35.65%. Neurocrine Biosciences's return on equity of 13.72% beat Protalix BioTherapeutics's return on equity of 8.75%.

Neurocrine Biosciences has a consensus price target of $161.42, signalling upside risk potential of 70.12%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 453.44%. Given that Protalix BioTherapeutics has higher upside potential than Neurocrine Biosciences, analysts believe Protalix BioTherapeutics is more attractive than Neurocrine Biosciences.

Neurocrine Biosciences has a beta of 0.334, which suggesting that the stock is 66.575% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.351%.

Neurocrine Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Neurocrine Biosciences quarterly revenues are $627.7M, which are larger than Protalix BioTherapeutics quarterly revenues of $18.2M. Neurocrine Biosciences's net income of $103.1M is higher than Protalix BioTherapeutics's net income of $6.5M. Notably, Neurocrine Biosciences's price-to-earnings ratio is 28.84x while Protalix BioTherapeutics's PE ratio is 87.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences is 4.18x versus 4.07x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of 16.43% compared to Neurocrine Biosciences's net margin of -18.58%. Neurocrine Biosciences's return on equity of 13.72% beat Retractable Technologies's return on equity of -16.83%.

Neurocrine Biosciences has a consensus price target of $161.42, signalling upside risk potential of 70.12%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Neurocrine Biosciences has higher upside potential than Retractable Technologies, analysts believe Neurocrine Biosciences is more attractive than Retractable Technologies.

Neurocrine Biosciences has a beta of 0.334, which suggesting that the stock is 66.575% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Neurocrine Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Neurocrine Biosciences quarterly revenues are $627.7M, which are larger than Retractable Technologies quarterly revenues of $10.3M. Neurocrine Biosciences's net income of $103.1M is higher than Retractable Technologies's net income of -$1.9M. Notably, Neurocrine Biosciences's price-to-earnings ratio is 28.84x while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences is 4.18x versus 0.64x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of 16.43% compared to Neurocrine Biosciences's net margin of -118.53%. Neurocrine Biosciences's return on equity of 13.72% beat Stereotaxis's return on equity of -139.2%.

Neurocrine Biosciences has a consensus price target of $161.42, signalling upside risk potential of 70.12%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 155.68%. Given that Stereotaxis has higher upside potential than Neurocrine Biosciences, analysts believe Stereotaxis is more attractive than Neurocrine Biosciences.

Neurocrine Biosciences has a beta of 0.334, which suggesting that the stock is 66.575% less volatile than S&P 500. In comparison Stereotaxis has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.223%.

Neurocrine Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Neurocrine Biosciences quarterly revenues are $627.7M, which are larger than Stereotaxis quarterly revenues of $6.3M. Neurocrine Biosciences's net income of $103.1M is higher than Stereotaxis's net income of -$7.5M. Notably, Neurocrine Biosciences's price-to-earnings ratio is 28.84x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences is 4.18x versus 5.57x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.